BioSpectrum
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

Betta Pharmaceuticals and Mankind Pharma reach exclusive licensing agreement for Ensartinib

19 November 2026 | News

Ensartinib is a targeted therapy designed to inhibit ALK, a protein that can drive cancer growth in a subset of patients with NSCLC



Delhi-based Mankind Pharma has entered into an in-licensing agreement with Betta Pharmaceuticals for Ensartinib, a novel, patented oncology drug approved by the US Food and Drug Administration (US FDA) and China's National Medical Products Administration (NMPA).

The drug is indicated for adult patients with anaplastic lymphoma kinase (ALK)-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK inhibitor.

Under the terms of the license agreement, Mankind Pharma will pay Betta Pharmaceuticals an upfront payment, potential development and sales milestone payments, and royalty payments on the annual net sales of Ensartinib in India. Mankind Pharma will be granted an exclusive license to develop, manufacture, register, and commercialise Ensartinib in India, subject to the terms and conditions of the license agreement.

The agreement marks another step in Mankind Pharma's efforts to strengthen its oncology portfolio through strategic collaborations with global pharmaceutical innovators and expand its presence in specialised therapies.